CIC1428 - BIOTHERIS - Clinical Research Center

The CIC BIOTHERIS is a Clinical Research Center dedicated to the development of in situ immunotherapy, an innovative approach that involves the direct administration of biotherapies with the goal of transforming the tumor into a patient-specific vaccine against their cancer.

Operating under the supervision of Inserm, the DGOS, Gustave Roussy, and Paris-Saclay University, its mission is to accelerate the development of new strategies for intra-tumoral immunotherapy in order to improve treatment efficacy while reducing systemic toxicity.

The center’s activities span the entire spectrum of clinical development, from early-stage “first-in-human” trials to advanced-phase multicenter trials. The main areas of research focus on intratumoral immunotherapies, oncolytic viruses, messenger RNA, immunomodulatory antibodies, and strategies combining interventional radiology and immuno-oncology. The CIC BIOTHERIS also develops innovative approaches to locoregional administration and analysis of the tumor microenvironment, in conjunction with translational and preclinical research programs.

CIC BIOTHERIS is now recognized as a major player in interventional immunotherapy, with publications in *Nature*, *Clinical Cancer Research*, the *Journal for ImmunoTherapy of Cancer*, and *Annals of Oncology*. In 2026, the NIVIPIT study, published in *Nature*, demonstrated that intratumoral administration of ipilimumab reduced severe toxicities by more than half while maintaining antitumor efficacy in patients with metastatic melanoma. This research has also identified new biomarkers predictive of response and contributes to the international reputation of French research in immunotherapy.

TSELIKAS Lambros - Unit Director, 
PUPH - University Professors and Hospital
Practitioners Employer: Gustave Roussy

MARABELLE Aurélien - Deputy Unit Director, 
PUPH - University Professors and Hospital Practitioners 
Employer: Gustave Roussy

AMMARI Samy 
PH - Hospital Practitioner 
Employer: Gustave Roussy

BACHROUCHE Diana 
IE - Research Engineer or equivalent 
Employer: Gustave Roussy

BAHLEDA Ratislav 
PH - Hospital Practitioner 
Employer: Gustave Roussy

BONNET Baptiste 
PhD Candidate 
Employer: Gustave Roussy

DANLOS François-Xavier 
PH - Hospital Physician 
Employer: Gustave Roussy

FUMET Jean-David 
Postdoc - Postdoctoral Researcher 
Employer: Gustave Roussy

GUIBOURT Mélanie 
Other AP - Other status, including apprentices 
Employer: Gustave Roussy

LEFRANC Caroline 
Other AP - Other status, including apprentice 
Employer: Gustave Roussy

MARTINEAU Romane 
Doc - Doctoral Student 
Employer: Paris-Saclay University

MOHAMED-DJALIM Chifaou 
AP - Other status, including apprentice 
Employer: Gustave Roussy

Geneviève PETRAULT NETO 
Other AP - Other status, including apprentices 
Employer: Gustave Roussy

PRUD'HOMME Clara 
Doc - Doctoral Student 
Employer: APHP

SAKKAL Madona 
PH - Hospital Practitioner 
Employer: Gustave Roussy

SUSINI Sandrine 
IR - Research Engineer or equivalent 
Employer: Gustave Roussy

TIHIC Edi 
IE - Design Engineer or equivalent 
Employer: Gustave Roussy

XHEPA Genti 
Postdoc - Postdoctoral Researcher 
Employer: Gustave Roussy

• Tselikas L, et al. Safety and efficacy of intratumoral anti-CTLA-4 combined with intravenous anti-PD-1. Nature. 2026. 10.1038/s41586-026-10341-w
• Meyblum L, et al. Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice. J Immunother Cancer. 2023;11(11):e007433. 10.1136/jitc-2023-007433
• Tselikas L, et al. Feasibility, safety, and efficacy of human intratumoral immunotherapy in cancer: a systematic review. Eur J Cancer. 2022;172:257–268. 10.1016/j.ejca.2022.05.024
• Tselikas L, et al. Interventional Radiology for Local Immunotherapy in Oncology. Clin Cancer Res. 2021;27(10):2698-2705. 10.1158/1078-0432.CCR-19-4073
• TSELIKAS L, et al. Pickering emulsions with ethiodized oil and nanoparticles for slow release of intratumoral anti-CTLA-4 immune checkpoint antibodies. J Immunother Cancer. 2020;8(1):e000579. 10.1136/jitc-2020-000579

• WO2024251978A1 (Drug Conjugate Targeting CTLA4, Products Comprising the Same, and Therapeutic Uses Thereof)
• EP4430403A1 (Products and Their Uses for Predicting a Subject's Sensitivity to Cancer Immunotherapy and for Selecting Optimized Therapy)